Financial Contrast: Genocea Biosciences (NASDAQ:GNCAQ) versus Vericel (NASDAQ:VCEL)

Genocea Biosciences (NASDAQ:GNCAQ) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Genocea Biosciences and Vericel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	N/A	N/A
Vericel	-1.61%	-1.55%	-1.02%

Analyst Ratings

This is a breakdown of current recommendations for Genocea Biosciences and Vericel, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	N/A
Vericel	0	0	6	0	3.00

Vericel has a consensus target price of $46.40, indicating a potential downside of 1.59%. Given Vericel’s higher probable upside, analysts clearly believe Vericel is more favorable than Genocea Biosciences.

Earnings and Valuation

This table compares Genocea Biosciences and Vericel’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.64 million	N/A	-$33.20 million	N/A	N/A
Vericel	$197.52 million	11.55	-$3.18 million	($0.09)	-523.83

Vericel has higher revenue and earnings than Genocea Biosciences.

Risk & Volatility

Genocea Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.